Integrated healthcare company running CVS pharmacies, Aetna health insurance and Caremark pharmacy-benefit management.
Integrated healthcare company running CVS pharmacies, Aetna health insurance and Caremark pharmacy-benefit management.
Earns from four linked businesses: pharmacies; Caremark, which negotiates drug prices for employers and insurers and earns fees and rebates; Aetna's insurance premiums; and primary-care clinics bought through Oak Street Health in 2023. Insurance and pharmacy benefits make up most of the revenue.
Moat: narrow (scale, distribution, switching costs). Vertical integration across pharmacy, PBM and insurance creates scale advantages and data lock-in.
Headquarters: Woonsocket, Rhode Island, US · Founded: 1963 · Employees: 300,000
Size CVS Health (CVS) is a United States Health Care company (Drugstore Chains) with a market value of $104B, the 120th largest of 3,085 United States companies the cockpit tracks. Shares closed at $81.35 on 18 Nov 2026.
Performance Over six months the shares fell 12.8%, against +22.5% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 6.8% over the last twelve months (peer median +8.5%); the operating margin is 3.6% (peer median 20.4%).
Valuation It trades at 9.6× forward earnings against a peer median of 17.7× (3rd cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.6 points above its cost of capital (7.0% WACC).
Credit CVS Health has 36 bonds outstanding ($55.8B), rated BBB by the agencies and trading like BBB at a weighted spread of 101 bp.
Short interest Short interest is 1.4% of the free float (30 Oct 2026).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $421B | $402B | $373B | $358B | $323B |
| Revenue growth | — | +8% | +4% | +11% | — |
| Gross profit | $59.8B | $55.4B | $51.3B | $54.9B | $54.8B |
| EBITDA | $19.8B | $17.1B | $14.5B | $19.9B | $20.8B |
| Net income | $11.0B | $1.77B | $4.61B | $8.34B | $4.31B |
| Free cash flow | $15.6B | $7.81B | $6.33B | $10.4B | $13.4B |
| Capital expenditure | $3.14B | $2.83B | $2.78B | $3.03B | $2.73B |
| Total debt | $75.3B | $80.0B | $82.9B | $79.4B | $70.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CVS Health CVS | $104B | -13% | +7% | 4% | 9.6× | -3.8% |
| UnitedHealth UNH | $314B | -8% | +3% | 5% | 15.4× | 3.1% |
| Cigna CI | $75.2B | +1% | +7% | 4% | 8.8× | -3.8% |
| Cencora COR | $66.5B | +32% | +5% | 1% | 17.7× | -1.2% |
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CVS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.1% | +2.1% | 2nd lowest of 21 |
| 6-month return | -12.8% | +22.5% | 2nd lowest of 21 |
| Distance from 52-week high | -26.5% | -10.5% | 4th lowest of 21 |
| Revenue growth (TTM) | +6.8% | +8.5% | 8th lowest of 21 |
| Operating margin | 3.6% | 20.4% | 5th lowest of 21 |
| Forward P/E | 9.6× | 17.7× | 3rd cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -3.8% | 5.8% | 5th least demanding of 20 |
| Growth delivered (Del g) | +8.4% | +9.5% | 8th lowest of 20 |
| Hurdle (Req g minus delivered) | -12.2 pp | -6.0 pp | 6th least demanding of 20 |
| ROIC minus cost of capital | +1.6 pp | +8.5 pp | 5th lowest of 18 |
| Net debt / EBITDA | 3.0× | 1.6× | 2nd most indebted of 18 |
| Bond spread | 101 bp | 78 bp | 2nd widest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CVS Health CVS | United States | $104B | -13% | +7% | 4% | 9.6× | -3.8% | +8.4% |
| HCA Healthcare HCA | United States | $99.5B | +20% | +6% | 15% | 15.6× | 3.1% | +8.0% |
| Regeneron Pharmaceuticals REGN | United States | $97.8B | +46% | +19% | 30% | 11.8× | -1.1% | +11.0% |
| Stryker SYK | United States | $121B | -1% | +8% | 25% | 19.9× | 10.7% | +11.8% |
| Bristol Myers Squibb BMY | United States | $122B | +3% | +4% | 33% | 9.2× | -13.1% | +2.5% |
| Elevance Health ELV | United States | $86.6B | +2% | +4% | 4% | 13.9× | 4.3% | +10.3% |
| McKesson MCK | United States | $125B | +44% | +8% | 2% | 22.1× | -5.5% | +11.1% |
| Medtronic MDT | United States | $129B | +30% | +10% | 20% | 16.8× | 9.1% | +3.8% |
| Vertex Pharmaceuticals VRTX | United States | $136B | +25% | +11% | 35% | 28.5× | 6.2% | +14.2% |
| Moderna MRNA | United States | $79.6B | +309% | +13% | -116% | n/a | n/a | n/a |
| Cigna CI | United States | $75.2B | +1% | +7% | 4% | 8.8× | -3.8% | +11.4% |
| Intuitive Surgical ISRG | United States | $146B | -6% | +20% | 32% | 34.8× | 29.6% | +18.2% |
| Pfizer PFE | United States | $160B | +9% | +1% | 26% | 9.9× | -4.3% | +8.5% |
| Danaher DHR | United States | $161B | +34% | +6% | 21% | 25.1× | 20.8% | +2.0% |
| Cencora COR | United States | $66.5B | +32% | +5% | 1% | 17.7× | -1.2% | +9.5% |
| Cardinal Health CAH | United States | $64.3B | +40% | +10% | 1% | 21.1× | 7.8% | +9.4% |
| Boston Scientific BSX | United States | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% | +15.2% |
| Edwards Lifesciences EW | United States | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% | +6.7% |
| Abbott Laboratories ABT | United States | $181B | +18% | +10% | 14% | 17.9× | 16.5% | +5.1% |
| argenx SE Sponsored ADR ARGX | United States | $59.1B | +17% | +71% | 29% | 29.0× | 11.7% | +151.4% |
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
CVS Health has 36 bonds outstanding with $55.8B face value. The agencies rate it BBB; its bonds trade like BBB. Weighted yield 5.92%, a spread of 101 bp over government bonds.